Cresco Labs, based in Chicago, is involved in FDA psychedelic research trials, though the company is struggling with unfeasible profitability due to market fragmentation.
2 reports, 2 independent
Updated Aug 25
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cresco Labs, based in Chicago, is involved in FDA psychedelic research trials, though the company is struggling with unfeasible profitability due to market fragmentation.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Chicago
city and county seat of Cook County, and largest city in State of Illinois, United States of America
-
Cresco Labs
American cannabis company
- FDA
Related events
- An Executive Order has been issued mandating accelerated research into psychedelic therapies through partnerships between various bodies.
- Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.
- Richard Langford provided expert comments on psychedelic drug access and is receiving feedback on clinical psychedelic programs.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Coverage
Newest first; wire copies grouped- pr-inside.com
- Market ExclusiveWeekly Roundup on the Cannabis Sector & Psychedelic Sector Key Takeaways; Cannabis Sector Cannara Biotech secured 5 vape cartridge listings in Québec market launch Cresco Labs exited California marke